PT  - JOURNAL ARTICLE
AU  - Kanhaiyalal Agrawal
AU  - P Sai Sradha Patro
AU  - C Preetam
TI  - Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer
AID  - 10.1136/bcr-2018-227910
DP  - 2019 Apr 01
TA  - BMJ Case Reports
PG  - e227910
VI  - 12
IP  - 4
4099  - http://casereports.bmj.com/content/12/4/e227910.short
4100  - http://casereports.bmj.com/content/12/4/e227910.full
SO  - BMJ Case Reports2019 Apr 01; 12
AB  - There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS). These patients are less benefited with I-131 therapy and surgery remains only curable option if disease could be localised. If surgery is not feasible, other therapeutic options are not promising. However, if these patients show strongly positive SSTR imaging, then possibility of peptide receptor radionuclide therapy may be explored. As SSTR PET-CT imaging is expensive and not widely available, Technetium-99m (Tc-99m) hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC), which is a Single photon emission computed tomography (SPECT) tracer, can be used. We are documenting a case of raised serum thyroglobulin antibody and negative I-131 whole body scan with disease recurrence localised on Tc-99m HYNIC-TOC scan.